Acute Myelogenous Leukemia (Acute Myeloid Leukemia)

Acute Myelogenous Leukemia (Acute Myeloid Leukemia – AML) – Treatment Options

Introduction
Acute myelogenous leukemia (AML), also called acute myeloid leukemia, is a heterogeneous hematologic malignancy characterized by clonal proliferation of myeloid precursors with impaired differentiation. It leads to bone marrow failure, presenting with anemia, infections, bleeding, and sometimes leukostasis, gingival hypertrophy, or skin infiltration. Prognosis and therapy depend on cytogenetics, molecular mutations, age, and performance status. Management integrates intensive chemotherapy, targeted agents, and stem cell transplantation in selected patients.

1. Initial Stabilization and Supportive Care

• Hospital admission with protective isolation.

• Blood product support:

  • Packed red blood cells for symptomatic anemia.

  • Platelets to maintain counts >10,000/µL (or >20,000–50,000/µL if bleeding risk).

• Infection management:

  • Empiric broad-spectrum antibiotics for febrile neutropenia.

  • Antifungal and antiviral prophylaxis in high-risk patients.

• Tumor lysis syndrome prevention: IV hydration, allopurinol, or rasburicase.

• Central venous access: For chemotherapy and transfusions.

2. Induction Therapy (Remission Induction)

• Standard regimen – “7 + 3”:

  • Cytarabine: Continuous IV infusion for 7 days.

  • Anthracycline (daunorubicin or idarubicin) for 3 days.

• Goal: Achieve complete remission (CR) with <5% blasts in marrow and recovery of hematopoiesis.

• Alternative/intensified regimens:

  • FLAG-IDA (fludarabine, cytarabine, G-CSF, idarubicin) for refractory cases.

  • CPX-351 (liposomal cytarabine + daunorubicin) for secondary AML or AML with myelodysplasia-related changes.

• Targeted additions:

  • Midostaurin in FLT3-mutated AML.

  • Gemtuzumab ozogamicin in CD33-positive AML.

3. Consolidation Therapy

• High-dose cytarabine (HiDAC): Standard for younger, fit patients with favorable/intermediate risk.

• Allogeneic hematopoietic stem cell transplantation (HSCT):

  • For high-risk or relapsed AML.

  • Offers curative potential but carries transplant-related risks.

4. Targeted and Novel Therapies

• FLT3 inhibitors: Midostaurin (frontline), gilteritinib (relapsed/refractory).

• IDH inhibitors: Ivosidenib (IDH1), enasidenib (IDH2).

• BCL-2 inhibitor: Venetoclax with azacitidine, decitabine, or low-dose cytarabine, especially in elderly/unfit patients.

• Hypomethylating agents: Azacitidine or decitabine for older or frail patients.

5. Special Considerations

• Acute promyelocytic leukemia (APL, AML M3 subtype): Managed with all-trans retinoic acid (ATRA) + arsenic trioxide (± anthracyclines), with high cure rates.

• Elderly/unfit patients: Low-intensity regimens (hypomethylating agents ± venetoclax, or low-dose cytarabine).

• Leukostasis (hyperleukocytosis): Cytoreduction with leukapheresis and hydroxyurea.

6. Monitoring and Long-Term Care

• Minimal residual disease (MRD): Assessed by flow cytometry or PCR for prognostic guidance.

• Bone marrow biopsies: After induction and during follow-up to confirm remission.

• Toxicity surveillance: Cardiac monitoring (anthracyclines), renal/hepatic function, fertility considerations.

• Survivorship care: Monitor for relapse, secondary cancers, endocrine and neurocognitive complications.

7. Multidisciplinary Care

• Hematology/Oncology teams: For chemotherapy and transplant planning.

• Transplant specialists: For HSCT evaluation.

• Infectious disease experts: For antimicrobial prophylaxis and therapy.

• Cardiologists, nephrologists, endocrinologists: For managing chemotherapy-related toxicities.

• Psychosocial and palliative care support: For quality of life and holistic management.